Further cash for GSK shareholders as Aspen fronts £164 million for RoW OTC products
This article was originally published in Scrip
South African company Aspen has agreed to acquire a basket of over-the-counter products from GlaxoSmithKline for R2.1 billion (£164 million), for markets outside Europe and North America. The products, which include Phillips Milk of Magnesia, the pain relief brand Solpadeine, the low-dose aspirin Cartia, the antiseptic brand Dequadin and the antacid Zantac (ranitidine), generated sales in the territories concerned of about £60 million last year.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.